Century Therapeutics (NASDAQ: IPSC) completed a $135 million private placement, issuing roughly 117.4 million shares of common stock (or pre‑funded warrants) and 58.7 million warrants at $1.15 per share. The transaction was led by TCGX and attracted participation from RA Capital Management, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, and the T1D Fund.
The proceeds will be directed toward advancing the company’s lead product candidate, CNTY‑813, a beta‑islet cell therapy for type 1 diabetes, as well as working capital and general corporate purposes. The financing extends Century’s cash runway to the first quarter of 2029, providing a buffer that supports the planned IND submission in 2026 and the first clinical data release in 2027.
CNTY‑813 is built on Century’s proprietary iPSC‑derived cell platform and Allo‑Evasion™ 5.0 immune‑evasion technology, designed to prevent immune rejection without chronic immunosuppression. Preclinical studies have shown durable glycemic control in animal models, positioning the program as a potentially curative approach to a disease with limited treatment options.
The announcement was well received by investors, generating a notable positive market reaction. The financing signals strong confidence from a cohort of prominent healthcare investors and underscores the company’s progress toward clinical milestones.
"We estimate this financing extends our cash runway to Q1 2029 with an anticipated IND submission for CNTY‑813 in 2026 and initial clinical data expected in 2027," said CEO Brent Pfeiffenberger. "This funding further enables our ambition to unlock the full potential of our lead product candidate, a potentially curative beta‑islet cell program for type 1 diabetes.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.